KalVista Pharma Terminates KVD824 Phase 2 KOMPLETE Trial For Prophylactic Treatment Of HAE

RTTNews | vor 913 Tagen
KalVista Pharma Terminates KVD824 Phase 2 KOMPLETE Trial For Prophylactic Treatment Of HAE

(RTTNews) - KalVista Pharmaceuticals, Inc. (KALV) announced Monday that it has terminated the KOMPLETE phase 2 clinical trial for KVD824 for the prevention of attacks in people with hereditary angioedema (HAE).

This decision was based on the observation of liver enzyme (ALT/AST) elevations in multiple patients in all treatment groups of the trial. No patients had concomitant elevation of bilirubin levels and all were asymptomatic.

The KOMPLETE trial is a phase 2 clinical trial evaluating KVD824, an investigational oral plasma kallikrein inhibitor designed for the prevention of attacks in adults living with HAE.

Patients in the trial were randomized to one of three treatment groups, each placebo controlled: 300 mg, 600 mg, 900 mg KVD824 (or placebo), all dosed twice daily.

KalVista continues to recruit the phase 3 KONFIDENT trial assessing sebetralstat (formerly KVD900) as a potential oral, on-demand therapy for HAE attacks, with data anticipated in the second half of 2023.

For More Such Health News, visit rttnews.com

read more
KalVista Pharma Appoints Brian Piekos As New CFO

KalVista Pharma Appoints Brian Piekos As New CFO

KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the biotechnology sector.
RTTNews | vor 206 Tagen
Pound Falls As European Shares Extend Losses On Growth Worries

Pound Falls As European Shares Extend Losses On Growth Worries

The British pound weakened against other major currencies in the European session on Friday, as European shares traded lower, extending steep losses from the previous session after U.S. President Donald Trump announced significantly harsher-than-expected tariffs.
RTTNews | vor 4Std 44 Minuten
DAX Down 2.2% As Stocks Extend Recent Plunge

DAX Down 2.2% As Stocks Extend Recent Plunge

After suffering its worst setback in about eight months on Thursday, the German market is deep down in negative territory again with stocks reeling under a fresh bout of selling pressure on Friday amid concerns about growth following U.S. President Donald Trump's tariff moves.
RTTNews | vor 4Std 48 Minuten
Pound Falls Against Majors

Pound Falls Against Majors

The British pound weakened against other major currencies in the European session on Friday.
RTTNews | vor 5Std 25 Minuten
European Shares Extend Losses On Growth Worries

European Shares Extend Losses On Growth Worries

European shares traded lower on Friday, extending steep losses from the previous session after U.S. President Donald Trump announced significantly harsher-than-expected tariffs.
RTTNews | vor 5Std 29 Minuten